KALA BIO (NASDAQ:KALA) Announces Quarterly Earnings Results, Beats Expectations By $0.50 EPS

KALA BIO (NASDAQ:KALA) released its quarterly earnings results on Tuesday. The company reported ($1.93) EPS for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50, Zacks reports.

KALA BIO Stock Performance

Shares of KALA stock traded down $0.19 during trading on Thursday, hitting $6.76. The company’s stock had a trading volume of 14,006 shares, compared to its average volume of 84,138. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 1.97. The company has a market cap of $31.15 million, a PE ratio of -0.54 and a beta of -2.13. The business has a fifty day moving average of $6.00 and a 200-day moving average of $6.29. KALA BIO has a 52 week low of $4.21 and a 52 week high of $10.97.

Analysts Set New Price Targets

Separately, Oppenheimer reiterated an “outperform” rating and issued a $15.00 target price on shares of KALA BIO in a research note on Monday, August 19th.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.